News for Seer, Inc. (SEER)

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its DecisionDx-Mel

The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Fourth Quarter Revenue: $4 million, a decrease of 10% from $4.4 million in Q4 2023.Full Year Revenue: $14.2 million, a decrease of 15% from $16.7 million in 20

Feb 27, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the Seer fourth quarter and full year 2024 earnings conference call. (Ope

Seer, Inc. (NASDAQ:SEER) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsCarrie Mendivil - Investor RelationsOmid Farokhzad...

Seer (SEER) delivered earnings and revenue surprises of 15% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: Achieved $4.0 million for Q4 2024, slightly surpassing the estimated $3.95 million.Earnings Per Share (EPS): Reported a loss of $0.37 per share for Q4

Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technol

Seer Inc (SEER) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $3.95 million, and the earnings are expect

PR NewswireMENLO PARK, Calif., Feb. 25, 2025 MENLO PARK, Calif., Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose missio

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requir

**media[540330]**

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administ

PR NewswireRALEIGH, N.C. and TEL-AVIV, Israel, Jan. 21, 2025 Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori ther

DATROWAY ® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

PR NewswireSHELTON, Conn., Jan. 10, 2025 The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration autho

REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. ( SEER), a leading life sciences company commercializing a disruptive new platform for prot

**media[504487]**

PR NewswirePRINCETON, N.J., Dec. 16, 2024 FLASH2 Study opens patient enrollmentPRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX